Key facts
- It has raised $111.0M; the latest was Grant ($430K) in Oct 2024.
- Notable investors include Gates Foundation, Jefferies Financial Group, Royalty Pharma, Trinity Capital (Phoenix).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ApiJect
- ·The full record, as it builds
Funding rounds
No funding rounds for ApiJect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ApiJect
Manufacturer of breadth-first search prefilled syringes intended to be more affordable and widely available than existing glass vials and plastic or glass syringes. The company's technology replaces glass, aluminum, rubber, and silicone with a single material, medical-grade plastic resin, which results in a simplified supply chain and significantly reduced environmental impact, enabling pharma companies to provide liquid medicines and vaccines to safely reach more patients
- Sector
- Healthcare
- HQ
- Stamford, CT, United States
- Founded
- 2015
- Employees
- 65
- Website
- apiject.com/
- Ownership
- Privately Held (backing)
ApiJect doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ApiJect shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ApiJect in its N-PORT filings yet. We sweep new filings monthly.